Welcome to our dedicated page for EchoIQ news (Ticker: ECHQF), a resource for investors and traders seeking the latest updates and insights on EchoIQ stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EchoIQ's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EchoIQ's position in the market.
Echo IQ (ASX:EIQ / OTC:ECHQF) announced that CEO Dustin Haines will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 12:50 p.m. ET at the Lotte New York Palace.
The event will be webcast and is authorised for release by the company's board. Contact details for investor enquiries are provided for Andrew Grover and Six Degrees Investor Relations.
Echo IQ (OTC:ECHQF) highlighted two studies presented at AHA Scientific Sessions 2025 showing gaps in diagnosing and treating severe aortic stenosis (AS) and potential benefits of EchoSolv AS. A 30,878-echocardiogram investigator study found EchoSolv identified severe AS phenotypes more accurately than cardiologists and improved the male:female diagnosis ratio from 2.2:1 to 1.1:1. A separate real-world analysis of 1.18 million echocardiograms from NEDA linked to national health data found only 36% of women and 45% of men with moderate-to-severe AS received intervention and that “watchful waiting” was associated with substantial life-years lost. EchoSolv AS has FDA clearance and is positioned as a decision-support tool to reduce diagnostic delays and improve intervention timing.
FAQ
What is the current stock price of EchoIQ (ECHQF)?
